A round of financing from U.S. and Israeli investors has pulled in $7 million for Medigus. The Israeli company, which has developed the FDA-cleared SRS Endoscopic device designed to treat gastroesophageal reflux disease less invasively, will use part of the money to accelerate its expansion efforts in Europe and the U.S.

Related Summaries